2430

NEW ZEALAND GAZETTE

Prilocaine; for injection except when used as a local
anaesthetic by a dental therapist; except when specified
elsewhere in the Schedule

Propantheline

Protamine sulfate

Quinisocaine

Sabadilla; except when specified elsewhere in the Schedule

Silver sulfadiazine; except for external use in packs
containing 50 grams or less

Strychnos spp

Thiomesterone

Vardenafil

Schedule 2

Restricted Medicines

Erythryl tetranitrate

Hyoscine butylbromide; for oral use in medicines containing
not more than 10 milligrams per dose form and in packs
containing not more than 20 tablets or capsules

Mannityl hexanitrate

Podophyllum emodi; for external use for the treatment of
warts other than anogenital warts in medicines containing
20% or less and more than 10% of podophyllin

Podophyllum peltatum; for external use for the treatment of
warts other than anogenital warts in medicines containing
20% or less and more than 10% of podophyllin

Podophyllotoxin; for external use for the treatment of warts
other than anogenital warts in medicines containing 1% or
less and more than 0.5%

Prochlorperazine; in packs containing not more than
10 tablets for the treatment of nausea associated with
migraine or, when sold by pharmacists or nurses
accredited to sell levonorgestrel for emergency
contraception, for the treatment of nausea associated
with emergency contraception

Salicylic acid; in medicines containing more than 40%

Schedule 3

Pharmacy-only Medicines

Aciclovir; for external use for the treatment of herpes
labialis except in medicines containing 5% or less and in
tubes containing 3 grams or less

Amethocaine; for external use in medicines containing
10% or less and more than 2%

Atropa belladonna; for external use in medicines containing
0.03% of the alkaloids of belladonna; for oral use in
liquid form in medicines containing 0.03% or less and
0.3 milligrams or less per dose and not more than
1.2 milligrams per recommended daily dose of the
alkaloids of belladonna or in solid dose form in
medicines containing 0.3 milligrams or less per dose
form and not more than 1.2 milligrams per
recommended daily dose of the alkaloids of belladonna

Atropine; for oral use in liquid form in medicines containing
0.03% or less and 0.3 milligrams or less per dose and
not more than 1.2 milligrams per recommended daily
dose or in solid dose form in medicines containing
0.3 milligrams or less per dose form and not more than
1.2 milligrams per recommended daily dose; in
medicines containing atropine sulfate for the treatment
or organophoshorous poisoning either in packs of up
to 20 tablets containing 0.6 milligrams or less per
tablet or in injections in packs of 5 or less containing
0.6 milligrams per millilitre or less; except when used as
an antidote in a device designed for self-injection; except
when sold by licencees under the Toxic Substances
Regulations

Benzocaine; for external use in medicines containing 10%
or less and more than 2%

No. 90

Benzydamine; for external use

Bifonazole; for external use except in medicines for tinea
pedis only or in shampoos containing 1% or less

Cinchocaine; for external use in medicines containing 0.5%
or less

Datura spp; for oral use in liquid form in medicines
containing 0.03% or less and 0.3 milligrams or less per
dose and not more than 1.2 milligrams per recommended
daily dose of total solanaceous alkaloids or in solid
dose form in medicines containing 0.3 milligrams or less
per dose form and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids

Duboisia leichhardtii; for oral use in liquid form in medicines
containing 0.03% or less and 0.3 milligrams or less per
dose and not more than 1.2 milligrams per recommended
daily dose of total solanaceous alkaloids or in solid
dose form in medicines containing 0.3 milligrams or less
per dose form and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids

Duboisia myoporides; for oral use in liquid form in medicines
containing 0.03% or less and 0.3 milligrams or less per
dose and not more than 1.2 milligrams per recommended
daily dose of total solanaceous alkaloids or in solid
dose form in medicines containing 0.3 milligrams or less
per dose form and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids

Folic acid; in medicines containing more than 500
micrograms per recommended daily dose

Folinic acid; in medicines containing more than 500
micrograms per recommended daily dose

Hyoscine; for transdermal use in medicines containing
2 milligrams or less of total solanaceous alkaloids per
dose unit; for oral use in liquid form in medicines
containing 0.03% and 0.3 milligrams or less per dose
and not more than 1.2 milligrams per recommended
daily dose or in solid dose form in medicines containing
0.3 milligrams or less per dose unit and not more than
1.2 milligrams per recommended daily dose of total
solanaceous alkaloids

Hyoscyamine; for external use in medicines containing
0 03% or less of total solanaceous alkaloids; for oral use
in liquid form in medicines containing 0.03% and 0.3
milligrams or less per dose and not more than 1.2
milligrams per recommended daily dose or in solid dose
form in medicines containing 0.3 milligrams or less
per dose unit and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids

Hyoscyamus niger; for oral use in liquid form in medicines
containing 0.03% and 0.3 milligrams or less per dose
and not more than 1.2 milligrams per recommended
daily dose of total solanaceous alkaloids or in solid
dose form in medicines containing 0.3 milligrams or less
per dose unit and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids

Ibuprofen; for external use; for oral use in either liquid
form in packs containing not more than 4 grams or in
solid dose form containing not more than 200 milligrams
per dose form and when in medicines which have
received the consent of the Minister or the Director-General to their sale as pharmacy-only medicines and
which are sold in the manufacturer’s original pack

Lignocaine; for external use in medicines containing 10% or
less and more than 2%; for urethral use

Minoxidil; for external use in medicines containing 5% or
less

Nystatin; for dermal use

Podophyllum emodi; for external use for the treatment
of warts other than anogenital warts in medicines
containing 10% or less of podophyllin